Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.

PHASE4TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Diabetes Mellitus, Type 2Hypertension
Interventions
DRUG

Carvedilol Controlled Release (CR)

"lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study.~Initial dose: Carvedilol CR (20 mg QD, dose level 1) Titration: If tolerated, increase the dosage to 20 mg QD, 40 mg QD, and 80mg QD orally over successive intervals of at least 2 weeks to achieve target blood pressure sSBP \<130 and sDBP \< 80"

DRUG

lisinopril

lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study

Trial Locations (1)

14221

Diabetes - Endocrinology Center of Western New York, Buffalo

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University at Buffalo

OTHER